Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Summary
A Phase 3 Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
780
Start Date
2025-03-28
Completion Date
2026-06-30
Last Updated
2025-03-19
Healthy Volunteers
No
Conditions
Interventions
HDM1002 200mg, oral, once daily, 52 weeks
HDM1002 200mg, oral, once daily, 52 weeks
HDM1002 400mg, oral, once daily, 52 weeks
HDM1002 400mg, oral, once daily, 52 weeks
HDM1002 placebo, oral, once daily, 52 weeks
HDM1002 placebo, oral, once daily, 52 weeks